Sublingual immunotherapy in allergic rhinitis: Indications, efficacy and safety

Rhinology

Volumn 51, Issue 1, 2013, Pages

  Kariyawasam, Harsha H ^a   Rotiroti, Giuseppina ^a   Robinson, Douglas S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Allergic rhinitis; Immunotherapy; Sublingual

Indexed keywords

ALLERGEN;

HAY FEVER; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PERENNIAL RHINITIS; REVIEW; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; HUMANS; IMMUNOTHERAPY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

MLCS; MLOWN;

EID: 84874744869     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/rhino11.268     Document Type: Review

References (49)

1. Bousquet J, Khaltaev N, Cruz AA. et al. Allergic Rhinitis and its Impact on Asthma ARIA 2008 update in collaboration with the World Health Organization, GA2LEN and AllerGen. Allergy. 2008; 63 Suppl 86: 8-160
2. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy. 2007; 62: 301-309
3. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998; 1024 Pt 1: 558-562
4. Malling HJ. The position of immunotherapy in the European Academy of Allergology and Clinical Immunology. J Investig Allergol Clin Immunol. 1997; 7: 356-357
5. Canonica G.W., Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009; 64 Suppl 91: 1-59
6. Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011; 41: 1177-1200
7. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 1271 Suppl: S1-55
8. White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy. 1998; 28: 266-270
9. Mohapatra SS, Lockey RF, Shirley S. Immunobiology of grass pollen allergens. Curr Allergy Asthma Rep. 2005; 5: 381-387
10. Frew AJ. Hundred years of allergen immunotherapy. Clin Exp Allergy. 2011; 41: 1221-1225
11. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N Engl J Med. 1965; 273: 675-679
12. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007; 1: CD001936
13. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986; 16: 483-491
14. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol. 2011; 127: 974-981
15. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011; 127: 72-80, 80
16. Cox L, Compalati E, Canonica W. Will sublingual immunotherapy become an approved treatment method in the United States? Curr Allergy Asthma Rep. 2011; 11: 4-6
17. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003; 2: CD002893
18. Horak F, Wheeler AW. Oral hyposensitisation with enteric-coated allergens as extension therapy following a basic subcutaneous course of injections. Int Arch Allergy Appl Immunol. 1987; 84: 74-78
19. Bjorksten B, Moller C, Broberger U, et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy. 1986; 41: 290-295
20. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006; 97: 141-148
21. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010; 12: CD002893
22. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011; 7: CD007685
23. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual Corrected proof 9 Sublingual immunotherapy in allergic rhinitis immunotherapy for house dust mites respiratory allergy: results of a GA2LEN metaanalysis. Allergy. 2009; 64: 1570-1579
24. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy. 2011; 41: 1235-1246
25. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117: 802-809
26. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011; 127: 509-516
27. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy. 2007; 62: 958-961
28. Senna GE, Calderon M, Milani M. Allergy immunotherapy tablet: GrazaxR for the treatment of grass pollen allergy. Expert Rev Clin Immunol. 2011; 7: 21-27
29. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008; 121: 512-518
30. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass polleninduced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010; 125: 131-138
31. Durham SR. Sustained effects of grass pollen AIT. Allergy. 2011; 66 Suppl 95: 50-52
32. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 120: 1338-1345
33. Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass polleninduced rhinoconjunctivitis. J Allergy Clin Immunol. 2011; 128: 559-566
34. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009; 123: 160-166
35. Sabbah A, Hassoun S, Le SJ, Andre C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994; 49: 309-313
36. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy. 1998; 53: 493-498
37. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol. 2004; 114: 831-837
38. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009; 64: 1394-1401
39. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998; 53: 662-672
40. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy, 2004; 59: 45-53
41. Vervloet D, Birnbaum J, Laurent P, et al. Safety and efficacy of Juniperus ashei sublingual- swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol. 2007; 142: 239-246
42. La RM, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebocontrolled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999; 1042 Pt 1: 425-432
43. Andre C, Perrin-Fayolle M, Grosclaude M et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol. 2003; 131: 111-118
44. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004; 93: 425-430
45. Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59: 491-497
46. O'Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factorbeta and functional regulatory T cells. Am J Respir Crit Care Med. 2009; 180: 936-947
47. Guez S, Vatrinet C, Fadel R, Andre C. Housedust- mite sublingual-swallow immunotherapy SLIT in perennial rhinitis: a double- blind, placebo-controlled study. Allergy. 2000; 55: 369-375
48. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy. 2008; 63: 374
49. de GH, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009; 64: 963-964.